Patents by Inventor Frank Misselwitz

Frank Misselwitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REDUCING THE RISK OF CARDIOVASCULAR EVENTS
    Publication number: 20210023088
    Abstract: Combination therapy with rivaroxaban and aspirin successfully reduces the risk of cardiovascular events in patients who have coronary artery disease and/or peripheral artery disease.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 28, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Nancy Cook Bruns, Frank Misselwitz, John Eikelboom, Stuart J. Connolly, Salim Yusuf
  • Reducing the risk of cardiovascular events
    Patent number: 10828310
    Abstract: Combination therapy with rivaroxaban and aspirin successfully reduces the risk of cardiovascular events in patients who have coronary artery disease and/or peripheral artery disease.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 10, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Nancy Cook Bruns, Frank Misselwitz, John William Andrew Eikelboom, Stuart J. Connolly, Salim Yusuf
  • REDUCING THE RISK OF CARDIOVASCULAR EVENTS
    Publication number: 20190240231
    Abstract: Combination therapy with rivaroxaban and aspirin successfully reduces the risk of cardiovascular events in patients who have coronary artery disease and/or peripheral artery disease.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 8, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Nancy Cook Bruns, Frank Misselwitz, John William Andrew Eikelboom, Stuart J. Connolly, Salim Yusuf
  • Prevention and treatment of thromboembolic disorders
    Patent number: 9539218
    Abstract: The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: January 10, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Frank Misselwitz, Dagmar Kubitza, Son-Mi Park, Klaus Wehling
  • MICROANGIOPATHY TREATMENT AND PREVENTION
    Publication number: 20100160301
    Abstract: The present invention relates to the use of selective factor Xa inhibitors, in particular of oxazolidinones of the formula (I) for the treatment and/or prophylaxis of microangiopathies and also their use for the production of medicaments for the treatment and/or prophylaxis of microangiopathies.
    Type: Application
    Filed: September 27, 2006
    Publication date: June 24, 2010
    Applicant: BAYER HEALTHCARE AG
    Inventors: Elisabeth Perzborn, Frank Misselwitz
  • Coating of artificial surfaces of medical aids and instruments, and cleaning and/or pretreatment of catheters and other medical aids and instruments
    Publication number: 20100003542
    Abstract: The present invention relates to the use of factor Xa (FXa) inhibitors with anticoagulant action for the antithrombotic coating and/or treatment of artificial surfaces of medical aids and/or devices for the prevention of fibrin deposits and/or formation of blood clots and of thrombi, and the use of FXa inhibitors in the cleaning and/or pretreatment of catheters and other medical aids and devices.
    Type: Application
    Filed: July 16, 2007
    Publication date: January 7, 2010
    Applicant: BAYER SCHERING PHARMA AKTIENGESSELSCHAFT
    Inventors: Elisabeth Perzborn, Frank Misselwitz
  • Prevention and Treatment of Thromboembolic Disorders
    Publication number: 20090004265
    Abstract: The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
    Type: Application
    Filed: January 19, 2006
    Publication date: January 1, 2009
    Applicant: BAYER HEALTHCARE AG
    Inventors: Frank Misselwitz, Dagmar Kubitza, Son-Mi Park, Klaus Wehling